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PRESENTATION 
 
“New screening tests in early pregnancy: diagnosis and prevention” is the title chosen to present  
two papers I published during these three years.  
Conserva V, Signaroldi M, Mastroianni C, Stampalija T, Ghisoni L, Ferrazzi E. Distinction 
between fetal growth restriction and small for gestational age newborn weight enhances the 
prognostic value of low PAPP-A in the first trimester. Prenat Diagn. 2010 Oct;30(10):1007-9  
Conserva V, Muggiasca M, Arrigoni L, Mantegazza V, Edoardo Rossi E, Ferrazzi E. Recurrence 
and severity of abnormal pregnancy outcome in patients treated by low-molecular-weight-heparin: 
a prospective pilot study. J Matern Fetal Neonatal Med. 2011 Nov 29  
These two paper deal with subjects that are apparently different: the first paper studies the 
prognostic value of a placental marker measured in the first trimester, PAPP-A, for abnormal 
pregnancy outcomes, the second one investigates the possible role of low molecular weight heparin 
to improve the development of pregnancy in patients with previous abnormal pregnancy outcomes.  
Besides the specific clinical application of both results, the two studies assume the central role of 
placentation. A physiologic communication and balance in maternal-fetal interface allows a correct 
development of placenta from the earliest days of gestation to twenty four weeks of pregnancy, 
although the phenotypic outcome of this process can be clinically evaluated much later in 
pregnancy. These two papers tap into this silent and fundamental process in order to evaluate a 
potential for early diagnosis or prevention. 
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ABSTRACTS 
 
Distinction between fetal growth restriction and small for gestational age newborn weight 
enhances the prognostic value of low PAPP-A in the first trimester.  
Conserva V, Signaroldi M, Mastroianni C, Stampalija T, Ghisoni L, Ferrazzi E.  
Prenat Diagn. 2010 Oct;30(10):1007-9  
Objective Low levels of PAPP-A in maternal blood may become an early marker of obstetrical 
complications. The aim of this article was to sort out those outcomes consistently related to an 
abnormal placental vascular function and to evaluate their association with low levels of maternal 
serum PAPP-A in early pregnancy 
Methods We analyzed retrospectively a database of the first trimester combined screening of an 
Italian biotech company and investigated the correlation between PAPP-A value < 5th percentile,  
0.40 multiples of the median (MoM), and infants with birthweight below the 10
th
 percentile for 
gestational age (small for gestational age SGA), preterm delivery, GH and PE not associated with 
intra-uterine growth restriction (IUGR), IUGR isolated with an abnormal umbilical PI or associated 
with maternal GH-PE, placental abruption and intra-uterine fetal demise (IUFD) after 22 weeks of 
gestation. 
Results 1687 patients were analyzed. Overall pregnancy complications were observed in 31.4% of 
women with low PAPP-A and in 21.1% women with a PAPP-A value >0.4 MoM (P < 0.0001). 
Severe and early fetal growth restriction (<34 weeks) with abnormal umbilical PI or maternal PE, 
was significantly associated with low levels of PAPP-A (OR= 10, 95% CI 1.0–97, P = 0.02). No 
relationship was observed between SGA newborns and low PAPP-A. Weak association was 
observed in with GH and PE not associated with fetal growth restriction (OR = 1.9, 95% CI 1.1–3, 
P = 0.01). We also observed a correlation between low PAPP-A and preterm delivery (OR = 1.8, 
95% CI 1.1–2,9, P = 0.01). Because of the small number of cases, the OR for placental abruption 
and IUFD were not calculated 
Conclusions. Low values of PAPP-A are associated with abnormal obstetrical outcome. Evaluating 
separately growth-restricted fetuses and small for gestational age fetuses we observe that only 
growth-restricted fetuses are significantly associated with low values of PAPP-A, whereas SGA 
newborns, simply defined by their percentile rank, are not predicted by this test in the first trimester 
of pregnancy. 
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Recurrence and severity of abnormal pregnancy outcome in patients treated by low-
molecular-weight-heparin: a prospective pilot study. 
Conserva V, Muggiasca M, Arrigoni L, Mantegazza V, Edoardo Rossi E, Ferrazzi E 
 J Matern Fetal Neonatal Med. 2011 Nov 29  
Objective This prospective pilot study assesses the recurrence rate and severity of abnormal 
pregnancy outcome (APO), excluding early pregnancy complications, in pregnant patients, without 
acquired thrombophilia, treated by prophylactic doses of LMWH, independently from their 
congenital thrombophilic condition. 
Methods We recruited a cohort of 128 pregnant patients with previous APO; 100 of whom with 
APO and intrauterine growth restriction (IUGR), and 28 with maternal APO only. LMWH 
treatment was started at recruitment. Composite cross over recurrence rate IUGR, gestational 
hypertension, preeclampsia, HELLP, abruptio was analyzed. The main outcome measure was 
severe APOs with iatrogenic delivery ≤ 32 weeks of gestation.  
Results Median gestational age at LMWH treatment was 20 weeks. Severe APO decreased in 
treated pregnancies from 45% to 4% (R.R.=0.3, CI .95=0.2-0.8). This value was not significantly 
different in thrombophilic and non thrombophilic patients. When severe and minor complications 
were analyzed altogether the recurrence rate was 28%. In patients with APO and FGR in the index 
pregnancy, newborn weights were significantly better in the treated pregnancy: 1090g (1035-1145) 
vs. 850g (535-1200), P<0,01) 
Conclusions. Prophylactic regimen of LMWH significantly reduced the recurrence rate of severe 
composite APO in pregnancies affected in the index pregnancy by APO and fetal growth restriction 
or SGA newborns. This result was independent from the patients’ inherited thrombophilic 
conditions.  
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GENERAL INTRODUCTION 
Prior to implantation, the outer wall of the blastocyst is formed by a single layer of uninucleate 
trophectoderm cells. Contact with the maternal uterine interface induces local differentiation of this 
layer into an outer multinucleated syncytiotrophoblast, and an underlying population of progenitor 
cells, the cytotrophoblast cells (1).  
The maternal-fetal interface has certain unique features immunologically. It must exhibit immune 
tolerance to the allogenic syncytiotrophoblast, cytotrophoblast and fetus, and at the same time, it 
must maintain adequate protection against microbial invasion of the maternal host. The 
syncytiotrophoblast forms the terminally differentiated epithelial covering of the placental villous 
trees, being in direct contact with maternal blood and behaves, together with decidual cells, as ―non-
classical‖ immune cells at the utero-placental interface expressing toll-like receptors (TLR). These 
receptors at maternal-fetal interface not only recognize microorganisms, but also encode for genes 
resulting in release of cytokines, prostaglandins and coagulation factors (2). 
Cytotrophoblast cells can differentiate along either of two pathways. They may fuse with the 
overlying syncytiotrophoblast, thus increasing its mass. Alternatively, where villi make contact with 
the decidua they may differentiate along the extravillous pathway and invade the maternal tissues. 
In doing so, they start as interstitial trophoblast invading through the stroma of the decidua and then 
may remain interstitial or may follow two other routes, towards the lumen of spiral arteries as 
endovascular trophoblast (3), or towards the lumen of uterine glands as endoglandular trophoblast 
(4). The interstitial trophoblast normally penetrates as far as the inner third of the myometrium. 
Trophoblast development and differentiation are crucial processes for a physiologic pregnancy 
development. Any insult resulting in an aberrant development and differentiation of the villous 
syncytiotrophoblast poses a risk for the integrity of the placental barrier and the release of necrotic 
and aponecrotic trophoblast fragments, culminating in a systemic inflammatory response of the 
mother (5). This process is shown by the shift of normal Th1/ Th2 balance to Th2/ Th1, resulting in 
increased production of inflammatory cytokines  (6). Inflammation is known to play a pivotal role 
in pathogenesis of Preeclampsia (PE), and other obstetric complications including pretermlabor and 
chorioamnionitis (7) by the activation of circulating leukocytes in maternal blood, along with 
increased levels of particular subsets of leukocyte-derived microparticles (MP). Other markers of 
inflammatory change include Interleukin-1 Receptor Antagonist (IL-1RA) and tumor necrosis 
factor (TNF)-R1in women with PE, as compared to non-pregnant cohort (8). Local hemostatic 
changes in placental vasculature have been well defined (9). While there is expression of tissue 
factor (TF) in the synctiotrophoblast, there is a concomitant decrease in the concentration of tissue 
factor inhibitor pathway (TFPI) in the synctiotrophoblast. Furthermore, the balance between TF-
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TFPI has been found to be altered in women with gestational vascular complications. Select 
coagulation factors and global markers of coagulation activation have been partially characterized 
in women with placenta mediated complications. For example in women with pre eclampsia, 
coagulation abnormalities which have been identified include decreased antithrombin activity, 
elevated PAI-1 antigen and elevated Thrombin-Antithrombin (TAT) complexes (10). 
Biochemical and immunologic markers reflect the systemic responses of maternal systems to 
abnormal pregnancy and may be of an inflammatory or metabolic origin. 
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PART I 
 
DISTINCTION BETWEEN FETAL GROWTH RESTRICION AND SMALL FOR 
GESTATIONAL AGE NEWBORN WEIGHT ENHANCES THE PROGNOSTIC VALUE 
OF LOW PAPP-A IN THE FIRST TRIMESTER 
10 
 
INTRODUCTION 
 
The placentation, placenta itself and its myriad functions are central to successful reproductive 
outcomes. The placenta is the first complex mammalian organ to develop and as development 
continues, it becomes a robust endocrine organ, producing a spectrum of hormones that are unique 
to the pregnancy, such as human chorionic gonadotropin, estriol, as well as hormones identical to 
those produced elsewhere, such as estrogen and progesterone. This hormone production is 
intrinsically coupled to the physiologic changes of pregnancy and is critical for pregnancy 
maintenance.  
  
Biochemistry and biosynthesis of PAPP-A 
Pregnancy-associated plasma protein-A (PAPP-A) was first identified in 1974 (1). Circulating 
PAPP-A is principally derived from the syncytiotrophoblast (2,3), and the PAPP-A gene is located 
on human chromosome 9q33.1 (4). The protein is secreted as a disulfide-bound homodimer with a 
molecular weight of 400,000 g/mol (5). Each subunit consists of 1,547 amino acids (6) and includes 
modules known to occur in other proteins (Figure 1), but the degree of identity is generally low. A 
distinguishing feature is the metalloproteinase modules (MP), based on which PAPP-A is classified 
as a metzincin metalloproteinase, and hence related to the large family of matrix metalloproteinases. 
Other modules of PAPP-A include three Lin12-Notch repeat (LNR1-3) modules, a single laminin 
G-like module (LG), and five complement control protein modules (CCP1-5) that mediate binding 
of PAPP-A to heparan sulfates of cell surfaces. 
Almost all of the circulating PAPP-A is covalently bound to proMBP (proform of eosinophil major 
basic protein). During pregnancy, both PAPP-A and proMBP are expressed abundantly in the 
human placenta (7), but in different cell types. PAPP-A is principally expressed in the 
syncytiotrophoblast, whereas proMBP is expressed in extravillous cytotrophoblasts (2), from where 
it is secreted without propeptide cleavage. Thus, the process of PAPP-A/proMBP complex 
formation occurs in the extracellular environment, probably at the surface of the 
syncytiotrophoblast. PAPP-A bound to the cell surface readily forms a complex with proMBP, this 
complex is unable to bind to the cell surface and therefore enters the circulation.  
 
PAPP-A and the insulin-like growth factor system 
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Strong evidence suggests that PAPP-A increases the local bioavailability of insulin-like growth 
factor (IGF) by cleaving the inhibitors IGFBP-4 and −5 (insulin-like growth factor-binding protein-
4 and −5) (8). IGF is considered mitogenic and anti-apoptotic and is important for the growth of 
human cells in most tissues (9). This probably explains why PAPP-A knockout mice are reduced to 
60% of normal size at birth, strikingly similar to the IGF-II knockout mouse (10). Only dimeric 
PAPP-A, not the PAPP-A/proMBP complex, shows this proteolytic activity (5). At term, about 1% 
of the circulating PAPP-A is present as uncomplexed, active PAPP-A. However, the fraction of 
active PAPP-A is much higher in the first trimester, although the total level of PAPP-A is lower.  
 
Maternal serum levels of PAPP-A 
Maternal PAPP-A blood levels become detectable soon after implantation and increase throughout 
pregnancy, with a doubling time of 3–4 days during the first trimester and maximum levels at term 
(11,12) The rapid increase in PAPP levels during the first trimester causes the interpretation of a 
given value to be very dependent on gestational age. Common practice is therefore to use the unit 
MoM (Multiples of Median) as a gestational age-independent expression of PAPP-A concentration. 
The average half life of PAPP-A after normal delivery is 53 ± 26 hours (mean plus SD) (13). In 
addition to gestational age, a number of maternal and pregnancy-associated characteristics affect the 
maternal serum concentration of PAPP-A (Table 1). Some of these (multiple parity and smoking) 
are probably related to the mass of trophoblastic tissues, because the PAPP-A concentration 
increases with increasing ultrasound-determined placental volume (14). Other factors such as 
maternal pre-pregnancy weight have been correlated with the volume of distribution, whereas 
associations with parity, ethnicity, and assisted reproduction have so far escaped biological 
explanations. Several studies have tested the hypothesis that low maternal serum levels of 
pregnancy-associated plasma protein A (PAPP-A) may predict adverse pregnancy outcomes other 
than Down syndrome in first trimester (15- 20). Low levels of PAPP-A in maternal blood could 
become an early marker of obstetrical complications associated with poor placental function, that is 
small babies, gestational hypertension (GH), pre-eclampsia (PE), stillbirth and even premature 
delivery. However, contradictory results had been observed in different cohorts (19-21). These 
findings could result as a consequence of non-homogeneous criteria in the definition of different 
abnormal obstetrical outcomes. Recently, Poon et al. (22) showed that low PAPP-A is significantly 
associated with early PE but not with late PE.  This data confirmed the need to distinguish among 
abnormal obstetrical outcomes those based on similar placental damage. Moreover, when 
considering poor obstetrical outcomes, other environmental factors have to be taken into account. 
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Among these, maternal smoking has been largely studied while it is associated with impaired fetal 
growth. Therefore, this factor could interfere when evaluating the predictive value of PAPP-A.  
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AIM OF THE STUDY 
The aim of this article was to sort out among abnormal obstetrical outcomes those consistently 
related to an abnormal placental vascular function and to evaluate their association with low levels 
of maternal serum PAPP-A in early pregnancy. 
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METHODS AND RESULTS 
The database of the first trimester combined screening of an Italian biotech company (Bi-Tech 
Ltd.), certified by the Fetal Medicine Foundation (FMF), was analysed retrospectively by obstetrics 
and gynaecology specialists at the University Department of Clinical Sciences, University of Milan, 
under the regulations of a research contract. The database was searched for all combined first 
trimester screening tests in women with singleton pregnancies performed between January 2007 and 
January 2008. All women with high risk for trisomy 21, defined as risk greater than 1/350, were 
identified together with the women who presented intermediate risk, defined as risk 1/350 ÷ 1/1000. 
A control group of pregnant women at low risk for Down syndrome (<1/1000) was selected by 
means of a randomization table. The risk was evaluated by the combination of maternal age, nuchal 
translucency (NT) measurement, maternal serum-free β-hCG and PAPP-A. NT had been measured 
according to the FMF guidelines (23), while Bi-Tech Ltd. performed the analysis of serum 
metabolites and calculated the combined risk. PAPP-A values were corrected for maternal weight 
and smoking habit. Pregnancy outcome of all patients was obtained by telephone interviews 
conducted by a physician. Women with an aneuploid fetus diagnosed by invasive procedures or at 
birth filled an outcome form provided by the Bi-Tech company. In our cohort, the PAPP-A 5th 
percentile corresponded to 0.40 multiples of the median (MoM). This was used to define a low 
PAPP-A value and it is in accordance with previously observed results by Krantz et al. (16) and 
Dugoff et al. (16), respectively, 0.42 and 0.45 MoM. The following pregnancy complications were 
evaluated: (1) infants with birthweight below the 10
th
 percentile for gestational age (small for 
gestational age SGA); (2) preterm delivery <37 weeks of gestation; (3) GH and PE not associated 
with intra-uterine growth restriction (IUGR), the definition of GH and PE was according to the 
criteria proposed by Davey and MacGillivray (1988); (4) IUGR isolated or associated with GH or 
PE. IUGR was defined as decrement of the fetal abdominal circumference below the 10th percentile 
for local standard intra-uterine growth curves associated with an abnormal umbilical PI or maternal 
GH-PE. We also analysed the correlation of low PAPP-A with (5) placental abruption and (6) intra-
uterine fetal demise (IUFD) defined as fetal death after 22 completed weeks of gestation. Patients 
with more than one complication were counted only once, taking into account the most severe 
complication as shown in increasing order in this list. We performed univariate logistic regression 
model with maximum likelihood fitting to evaluate the correlation between PAPP-A and poor 
obstetrical outcomes and to estimate odds ratios (OR) and their corresponding 95% confidence 
interval (CI). To account simultaneously for the effects of maternal smoking and weight, we also 
performed a multiple logistic regression model (25). Statistical significance was assumed for P < 
0.05. Over the 12-months period, we identified 401 women with high risk and 867 with 
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intermediate risk for Down syndrome, while 502 subjects were randomly selected out of a larger 
sample (13 376) of women at low risk for chromosomal aneuploidies. The final sample size counted 
1770 participants. Pregnancy outcomes were available for the whole study population.  
Chromosomal abnormalities were diagnosed in 26 subjects and were excluded from the analysis. 
Spontaneous miscarriage <18 weeks of gestation occurred in 7 women. Gestational diabetes 
developed in 50 patients. These patients were also excluded from the final analysis, and the 
remaining 1687 patients were considered for the purpose of this study. Overall, pregnancy 
complications were observed in 31.4% (132/421) of women with low PAPP-A and in 21.1% 
(267/1266) women with a PAPP-A value >0.4 MoM (P < 0.0001). No significant differences 
between low and normal PAPP-A groups were observed for ethnicity (99.1% Caucasians vs 99.5%) 
and maternal age (33 years, i.r. 31–35 vs 33 years, i.r. 31–36). The frequency of smoking habit (9.5 
vs 6.2%, P value = 0.03) and maternal weight (63 kg, i.r. 56–72 vs 60 kg, i.r. 55–67, P value 
<0.001) were significantly different in two groups. Table 2 shows the comparison for the 
considered outcomes in the two groups, pregnant patients with low and normal PAPP-A and not 
adjusted and adjusted OR. Because of the small number of cases, the OR for placental abruption 
and IUFD were not calculated. Similarly, the distinction between the early (<34 weeks) and late 
onset (≥34 weeks) of adverse outcome was possible just for the IUGR group. The highest OR for 
abnormal outcome was observed for IUGR below 34 weeks of gestation, followed by adjusted OR 
for preterm delivery. SGA newborns were observed in about 10% of cases, both in women with low 
and normal PAPP-A.  
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DISCUSSION 
We observed that PAPP-A values below 0.40 MoM (5
th
 centile) in first trimester confer a higher 
relative risk for complications caused by placental vascular insufficiency and preterm delivery. 
Severe fetal growth restriction, in association with vascular placental damage as assessed by an 
abnormal umbilical PI or maternal PE, was significantly associated with low levels of PAPP-A in 
early pregnancy. When this association was evaluated for severe and early onset IUGR (<34 
weeks), the OR predicted by low PAPP-A in this cohort was up to 10 (95% CI 1.0–97, P = 0.02). 
By contrast, no relationship was observed between SGA newborns and low PAPP-A in the first 
trimester, whereas most studies demonstrated a positive predictive value of low PAPP-A for small 
for gestational age fetuses. Our result could be explained by the fact that we separated from the 
SGA group the IUGR group, that is those newborns whose growth was restricted due to severe 
placental insufficiency, as defined by an abnormal umbilical PI or maternal GH/PE. According to 
these criteria, the incidence of SGA that we observed in this cohort was around 10% as expected 
when the 10th percentile of a reference population is adopted to sort out SGA newborns. SGA are 
considered, by the definition itself, a normal biological variant, not necessarily associated with 
growth restriction. Weak associations were observed in pregnant women with GH and PE not 
associated with fetal growth restriction (not adjusted OR = 1.9); moreover, the OR adjusted for 
smoking habits and maternal weight was not significant. Thus, this ratio may not be clinically 
meaningful. We also observed a correlation between low PAPPA and preterm delivery (adjusted 
and not OR = 1.8). Preterm delivery is mainly caused by infection, placental vascular damage and 
stress (26). Therefore, it is conceivable from a biological point of view that low levels of PAPP-A 
in early gestation may result from vascular damage. We acknowledge that the main criticism to our 
report could be the small number of cases in the cohort. This is the reason we were not able to 
evaluate the correlation between the low PAPP-A and intra-uterine fetal death and placental 
abruption, as well as the distinction between early and late onset of adverse outcomes for all groups 
As reported (15,16,18), many of the associations between low PAPP-A levels and the adverse 
outcomes are statistically highly significant, but the sensitivity and positive predictive values for the 
individual outcomes are relatively low: one in ten pregnancies with low PAPP-A concentration 
resulted in PE with severe IUGR or severe IUGR with an abnormal umbilical PI. We conclude that 
low values of PAPP-A confirm their association with abnormal obstetrical outcome. However, the 
distinction between growth-restricted fetuses and small for gestational age fetuses allowed us to 
prove that only growth-restricted fetuses are significantly associated with low values of PAPP-A, 
whereas SGA newborns, simply defined by their percentile rank, are not predicted by this test in the 
first trimester of pregnancy. 
17 
 
REFERENCES 
1. Lin TM, Galbert SP, Kiefer D, Spellacy WN, Gall S. Characterization of four human pregnancy-
associated plasma proteins. Am J Obstet Gynecol. 1974;118:223–36.  
2. Bonno M, Oxvig C, Kephart GM, Wagner JM, Kristensen T, Sottrup-Jensen L, et al. Localization 
of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma 
protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger 
ribonucleic acid in placenta. Lab Invest. 1994;71:560–6.  
3. Tornehave D, Chemnitz J, Teisner B, Folkersen J, Westergaard JG. Immunohistochemical 
demonstration of pregnancy-associated plasma protein A (PAPP-A) in the syncytiotrophoblast of 
the normal placenta at different gestational ages. Placenta. 1984;5:427–31.  
4. Silahtaroglu AN, Tumer Z, Kristensen T, Sottrup-Jensen L, Tommerup N. Assignment of the 
human gene for pregnancy-associated plasma protein A (PAPPA) to 9q33.1 by fluorescence in situ 
hybridization to mitotic and meiotic chromosomes. Cytogenet Cell Genet. 1993;62:214–16.   
5. Overgaard MT, Sorensen ES, Stachowiak D, Boldt HB, Kristensen L, Sottrup-Jensen L, et al. 
Complex of pregnancy-associated plasma protein-A and the proform of eosinophil major basic 
protein. Disulfide structure and carbohydrate attachment. J Biol Chem. 2003;278:2106–17.  
6. Kristensen T, Oxvig C, Sand O, Moller NP, Sottrup-Jensen L. Amino acid sequence of human 
pregnancy-associated plasma protein-A derived from cloned cDNA. Biochemistry. 1994;33:1592–
8.  
7. Overgaard MT, Oxvig C, Christiansen M, Lawrence JB, Conover CA, Gleich GJ, et al. 
Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of 
eosinophil major basic protein: expression in human reproductive and nonreproductive tissues. Biol 
Reprod. 1999;61:1083–9.  
8. Laursen LS, Kjaer-Sorensen K, Andersen MH, Oxvig C. Regulation of insulin-like growth factor 
(IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein-4 and −5. Mol 
Endocrinol. 2007;21:1246–57 
9. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. 
Mol Cell Endocrinol. 1998;140:19–24.  
18 
 
10. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Fuchtbauer EM, et al. 
Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor 
during fetal development. Development. 2004;131:1187–94.  
11. Smith R, Bischof P, Hughes G, Klopper A. Studies on pregnancy-associated plasma protein A 
in the third trimester of pregnancy. Br J Obstet Gynaecol. 1979;86:882–7.  
12. Bischof P, DuBerg S, Herrmann W, Sizonenko PC. Pregnancy-associated plasma protein-A 
(PAPP-A) and hCG in early pregnancy. Br J Obstet Gynaecol. 1981;88:973–5.  
13. Bischof P, Amandruz M, Weil-Franck C, Baeriswyl JP, Weil A, Hermann WL, et al. The 
disappearance rate of pregnancy-associated plasma protein-A (PAPP-A) after the end of normal and 
abnormal pregnancies. Arch Gynecol. 1984;236:93–8.  
14. Plasencia W, Akolekar R, Dagklis T, Veduta A, Nicolaides KH. Placental volume at 11-13 
weeks' gestation in the prediction of birth weight percentile. Fetal Diagn Ther. 2011;30(1):23-8.  
15. Barrett SL, Bower C, Hadlow1 NC. 2008. Use of the combined firsttrimester screen result and 
low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diagn 28: 28–35. 
16. Dugoff L, Hobbins JC, Malone FD, et al. 2004. First-trimester maternal serum PAPP-A and 
free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are 
associated with obstetric complications: a population-based screening study (the FASTER Trial). 
Am J Obstet Gynecol 191: 1446–1451. 
17. Krantz D, Goetzl L, Simpson JL, et al. 2004. Association of extreme first-trimester free human 
chorionic gonadotropin-beta, pregnancyassociated plasma protein A, and nuchal translucency with 
intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191: 
1452–1458. 
18. Smith GCS, Shah I, Crossley JA, et al. 2006. Pregnancy-associated plasma protein A and alpha-
fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 107: 161–166. 
19. Spencer CA, Allen VM, Flowerdew G, et al. 2008a. Low levels of maternal serum PAPP-A in 
early pregnancy and the risk of adverse outcomes Prenat Diagn 28: 1029–1036. 
20. Spencer K, Cowans Nj, Molina F, et al. 2008b. First-trimester ultrasound and biochemical 
markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet 
Gynecol 31: 147–152. 
21. Kavak ZN, Basgul A, Koray E, et al. 2006. The efficacy of firsttrimester PAPP-A and free 
βhCG levels for predicting adverse pregnancy outcome. J Perinat Med 34: 145–148. 
19 
 
22. Poon LCY, Stratieva V, Piras S, Piri S, Nicolaides KH. 2010. Hypertensive disorders in 
pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 
11–13 weeks. Prenat Diagn 30: 216–223. 
23. Snijders RJ, Noble P, Sebire N, et al. 1998. UK multicentre project on assessment of risk of 
trisomy 21 by maternal age and fetal nuchaltranslucency thickness at 10–14 weeks of gestation. 
Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125): 343–346. 
24. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of 
pregnancy. Am J Obstet Gynecol. 1988 Apr;158(4):892-8. 
25. Breslow N, Powers W. Are there two logistic regressions for retrospective studies? Biometrics. 
1978 Mar;34(1):100-5 
 
 26. Goldenberg RL, Culhane JF, Iams JD, et al. 2008. Epidemiology and causes of preterm birth. 
Lancet 371(9606): 75–84. 
 
 
 
  
20 
 
Figure 1  legend 
The protein is secreted as a disulfide-bound homodimer with a molecular weight of 400,000 g/mol. 
Each subunit consists of 1,547 amino acids and includes modules known to occur in other proteins, 
but the degree of identity is generally low (A). Other modules of PAPP-A include three Lin12-
Notch repeat (LNR1-3) modules, a single laminin G-like module (LG), and five complement 
control protein modules (CCP1-5) that mediate binding of PAPP-A to heparan sulfates of cell 
surfaces. 
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Figure 1.  
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Table 1. Maternal and pregnancy-related factors influencing the level of PAPP-A in maternal serum 
during pregnancy. 
 Twins 1.86–2.12 MoM 
   Dichorionic  2.25 MoM 
   Monochorionic  1.76 MoM 
Mode of conception   
   IVF 0.80–0.90 MoM 
   ICSI  0.66–0.81 MoM 
Ethnicity (ratio)   
  Afro-Carribean vs. Caucasian  1.55–1.57 MoM 
  South Asian vs. Caucasian  1.03–1.08 MoM 
  East Asian vs. Caucasian 1.09–1.20 MoM 
Maternal pre-pregnancy weight   
  35–45 kg vs. all  1.55 MoM 
  115–125 kg vs. all  0.42 MoM 
Maternal smoking during pregnancy   
  Smoking in pregnancy  0.82–0.86 MoM 
 Nulliparous vs. multiparous  1.01–1.02 MoM 
 IDDM vs. no IDDM  0.80–1.01 MoM 
 Maternal HIV-infection vs. HIV-negative  0.84 MoM 
   
 
 
ICSI, intracytoplasmic sperm injection; IDDM, insulin dependent diabetes mellitus; IVF, in vitro 
fertilization; MoM, multiples of the median; PAPP-A, pregnancy-associated plasma protein-A. 
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Table 2 —Abnormal outcome in pregnant women with PAPP-A ≤0.40 MoM and >0.40 MoM and 
not adjusted and adjusted OR for maternal smoking and weight 
 
PAPP-A 
≤0.40 MoM 
(n = 421) 
n (%) 
PAPP-A 
>0.40 MoM 
(n = 1266 ) 
n (%) 
Not adjusted 
OR 
(95% CI) 
P value 
 
Adjusted OR 
(95% CI) 
P value 
 
Normal 
outcome 
289 (69) 
999 (79) 
 
    
SGA 48 (11.4) 131 (10.3) 1.1 (0.8–1.0) 0.54 1.3 (0.9–1.9) 0.10 
IUGR+ 
PE/GH or 
IUGR 
27 (6.4) 36 (2.8) 2.3 (1.4–3.9) 0.001 2.7 (1.6–4.6) 0.0002 
<34 weeks 5 1 10 (1.0–97) 0.02   
≥34 weeks 22 35 1.9 (1.2–3.4) 0.01   
GH-PE* 27 (6.4) 45 (3.6) 1.9 (1.1–3.0) 0.01 1.5 (0.9–2.4) 0.14 
PTD 27 (6.4) 46 (3.6) 1.8 (1.1–2.9) 0.01 1.8 (1.1–2.9) 0.02 
Abruptio 2 (0.5) 4 (0.3)     
IUFD >22 
weeks 
1 (0.2) 5 (0.4)     
 
* Twenty five patients with PE; 4 <34 weeks of gestation. 
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PART II 
 
RECURRENCE AND SEVERITY OF ABNORMAL PREGNANCY OUTCOME IN 
PATIENTS TREATED BY LOW-MOLECULAR-WEIGHT –HEPARIN: A PROSPECTIVE 
PILOT STUDY 
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INTRODUCTION  
 
 A dynamic balance of inflammatory cellular and molecular mechanisms dominates placental 
development and function to its end. An unbalanced inflammatory activation seems to play a 
dominant role for placental lesions linked to abnormal pregnancy outcomes (APO) such as IUGR, 
preeclampsia and abruption [1-2]. 
Accordingly, we hypothesize that low molecular weight heparin (LMWH) may be useful in patients 
with APO; mainly because of the role LMWH may play in the regulation of inflammation [3-4-5] 
rather than on its antithrombotic role [6-7].  
Potential benefits of LMWH could be due to enhancement of metalloproteasis, which may cause an 
improvement of trophoblastic invasion [8], or by its antiapoptotic role in placental cells [9], or even 
by its key role in complement activation inhibition 11 [10]. 
This background, together with many other recent studies induces to reconsider the original 
hypothesis of an antithrombotic usage of LMWH to prevent and treat abnormal obstetrical outcome. 
Indeed, many studies, challenging the correlation between congenital thrombophilia with APO, 
came almost to a dead end [11-12]. None of the large studies designed to achieve an adequate 
power observed but a weak odd ratio between congenital thrombophilia and APO [7]. 
Actually, Rey and co-workers [13] completely readdressed this issue of LMWH and thrombophilia 
simply by including in a randomized trial of LMWH only pregnant patients with previous APO, 
without thrombophilic conditions. In this case, patients treated with LMWH showed a significant 
reduction of APO versus non-treated patients. More recently Gris found similar significant 
reduction of recurrence of ischemic placental disease in pregnant women with previous HELLP 
syndrome randomized to LMWH vs. no treatment, independently from congenital thrombophilic 
condition and with the exclusion of women affected by antiphospholipid syndrome [14].  
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AIM OF THE STUDY 
The objective of this prospective pilot study was to assess the recurrence rate and severity of 
abnormal pregnancy outcome, excluding early pregnancy complications, in pregnant patients, 
without acquired thrombophilia, treated by prophylactic doses of LMWH, independently from their 
congenital thrombophilic condition. 
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MATERIALS AND METHODS  
Design of the study 
Starting in December 2001 to December 2008, we prospectively recruited a cohort of consecutive 
pregnant patients counseled for one or more previous APO at our interdisciplinary Centre for 
obstetrical immuno-haematolgy. 
All eligible patients were treated by prophylactic doses of LMWH from the time of recruitment. 
The standard dose was 4250 U.I. die of enoxaparin. In two cases of coexisting decrease of 
fibrinogen and increase of D-dimer it was increased to 8500 UI until delivery. 
When the study was commenced the prophylactic dose of LMWH for eligible patients had been a 
local standard of care in our interdisciplinary Center since 1998. In 2004, when the EMEA 
regulations for human research were accepted and enforced by the Italian law, this prospective 
observational study was communicated to the Ethical Committee and it was allowed to continue to 
its end with the same informed consent already in use which had been obtained by all patients. 
Patients with preeclampsia in their history were given also prophylactic low dose ASA at the time 
of recruitment. Each specific complication was treated according to local protocols, i.e. calcium-
antagonist and beta-blockers for hypertension, corticoids for Hellp syndrome. Fetal growth 
restriction was monitored according to the TRUFFLE protocol [15]. 
Inclusion criteria for this study were one or more of the following complications in the previous 
index pregnancy: 1) positive history of intrauterine death (IUFD) after 20 weeks of gestation and 
before 37 weeks of gestation, associated with weight below the 10th 22 percentile for local 
standards (SGA) 2) fetal growth restriction (IUGR) 3) gestational hypertension (GH) based on the 
standard pressure measurements above 140/90 and preeclampsia (PE) when GH  and 24 hours 
proteinuria above 300mg were recorded, 4) Hellp syndrome based on hemolysis, platelet count 
below 100.000 per ml and elevated liver enzymes, 5) clinical diagnosis of abruptio placentae. Early 
pregnancy loss was not considered an abnormal pregnancy outcome. Fetal growth restriction was 
defined as intrauterine assessment of restricted growth of the abdominal circumference according to 
local standards [16-17]. 
Exclusion criteria consisted of any of the following: gestational age at counseling >32 weeks of the 
current gestation; multiple gestation; a previous uneventful pregnancy; a previous  pregnancy 
treated with LMWH or UFH; patients with clinical immune disease and acquired thrombophilia - 
Lupus Like Anticoagulant (LAC) or antiphospholipid syndrome (APL); patients with positive 
antinuclear, anti mitochondria, anti smooth muscle antibodies; postnatal or post-mortem diagnosis 
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of congenital fetal anomaly or fetal 1 infection; women of non- Caucasian ethnicity; alcohol or 
illicit drug use; early pregnancy loss was not consider an abnormal pregnancy outcome. 
APO was grouped into two subsets: group 1 characterized by both maternal (GH, PE, HELLP, 
Abruptio) and fetal complications (IUGR and SGA with IUD), and group 2 with maternal 
complications only. 
We could classify previous pregnancy based on the letter of hospital discharge, not on the original 
clinical record. This allowed us to define a reliable diagnosis of specific APOs, whereas it was 
impossible to go through a detailed classification of severity for each given  complication. We 
introduced unequivocal clinical criteria to define a severe APO in the index pregnancy: any 
complication that led to an iatrogenic delivery ≤ 32 weeks of gestation. These same criteria were 
used to assess the overall severity of recurrence in the composite outcome of treated pregnancies. 
Women were studied for congenital thrombophilic conditions: Leiden mutation of factor V, 
prothrombin G20210A mutation, MTHFR homo-zygotic mutation and homocysteinemia, protein C, 
protein S. These examinations were available throughout the whole study.  
Additional more recent tests introduced during the study were not considered in this cohort. 
For each patient we recorded age, gestational age at the time of recruitment and the main indices of 
severity: gestational age at delivery, mode of delivery and neonatal survival. 
Follow-up was restricted to the early neonatal period or until discharge from the hospital of the 
mother and newborn. 
The study was completed after more than one hundred and thirty eligible patients were treated. 
Compliance to treatment and follow-up was unexpectedly high given the severe obstetric history. 
 
Statistics 
The sample size of 120 patients was calculated by considering a 25% recurrence rate of severe APO 
and hypothesizing that LMWH could reduce recurrence by 50%. We calculated that 120 patients 
would be enough to detect a significant difference, for α = 0.05, and a power of 98%. 
Baseline demographic data were analyzed by parametric and non-parametric descriptive statistics as 
appropriate. Incidence and severity of APO in the index pregnancy and in pregnancies treated with 
LMWH were analyzed and compared in the whole cohort, by parametric and non-parametric tests. 
The primary outcome was the recurrence of any severe APO that led to iatrogenic delivery ≤h32 
weeks of gestation. Relative risk (RR) was used to estimate the risk of recurrence of severe outcome 
in LMWH treated 1 pregnant patients. Chi Square test with Yates correction and Fisher exact tests 
were used as appropriate. In a second step the cohort was subdivided according to the presence or 
absence of any congenital thrombophilia, and recurrence rate and severity re-evaluated. A third 
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analysis was performed subdividing the cohort according to the gestational age at recruitment in 
order to observe the efficacy of timing of LMWH therapy. No missing data were observed in the 
limited items of retrospective information required. 
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RESULTS  
One hundred and thirty three Caucasian patients were eligible for this prospective study. One 
hundred and twenty eight completed the study. Mean maternal age was 34 years (interquartile range 
26-41). Parity was > 1 in 12 (9.3%) women. Median gestational age at initiation of LMWH therapy 
was 20 weeks (i.q. 12-27). Low dose ASA had been added to drug regimen in 45 patients with 
previous PE. 
Figure 1 shows the maternal and feto-maternal APO in the index pregnancy and in the treated 
pregnancy. The overall recurrence rate in the treated pregnancy was 28%, and not significantly 
different in the two groups (p=n.s.). Details on cross over recurrences of APO from feto-maternal to 
maternal only and vice versa are reported in tables Ia and Ib. The recurrence of severe APO in all 
treated pregnancies, independently from maternal or feto13  maternal APO in the index pregnancy, 
was 4% (R.R. = 0.3, CI 95% 0.2-0.8; Chi square test with Yates correction =0.003). In the group 
with abnormal feto-maternal outcome, newborn weight was significantly greater even in the treated 
pregnancy with severe APOs than in severe APO at index pregnancy: 1090g (1035-1145) vs. 850g 
(535-1200), (P<0,01). 
Neonatal mortality in the index pregnancy was 10%, no neonatal deaths occurred in the treated 
pregnancies. 
Table Ia shows the details of feto-maternal complications in index pregnancies and their cross over 
recurrence in treated pregnancies. In treated pregnancies not a single case of intrauterine fetal death 
was observed versus 44 cases of fetal intrauterine death associated with S.G.A. in the index 
pregnancy. GH or PE associated with IUGR recurred in only one case out of 17 cases observed in 
the index pregnancy. 
Severe cases delivered ≤ 32 weeks of gestation are flagged in the index pregnancy and in the treated 
pregnancy and reported both as absolute and overall relative figures. 
The R.R. for recurrence of severe APO in treated pregnancies was 0.3 (CI .95 = 0.1 – 0.8; Fisher 
exact test = 0.001). 
In this subset of patients with feto-maternal complications, 70 patients were treated ≤24 weeks of 
gestation. Median gestational age at LMWH therapy was 14 weeks (i.q. 10 – 18 completed weeks 
of gestation); recurrence rate of severe APO 3 of 70, overall recurrence rate was 20%. In 30 patients 
treatment was started ≥ 24 weeks of gestation. Median gestational age at LMWH therapy was 29 
week (i.q. 27 - 31 completed weeks of gestation); recurrence rate of severe APO was 1 of 30, 
overall recurrence rate was 37%. The Fischer exact test for overall APO recurrence in these two 
subsets was <0,08). 
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Table Ib shows the incidence of maternal complication in the index 1 pregnancy and the treated  
pregnancy. We found no cases of Hellp syndrome in the treated pregnancy and a decreased 
recurrence in abruptio placentae and GH, PE. 
Severe cases delivered ≤ 32 weeks of gestation are flagged in the index pregnancy and in the 
subsequent complicated pregnancy. The recurrence rate of severe cases was limited to one pregnant 
woman who developed a severe fetal growth restriction (980gr) The reduction of severe APO in 
treated pregnancies was not significantly different (Fisher exact test = 0.6). 
The R.R. was not calculated for this small group that was not large enough to accommodate the 
hypothesis of the power calculation. 
Fifty patients (39%) screened positive for congenital thrombophilia. Tables 2a and 2b show the 
recurrence rate and severity of maternal and feto-maternal complications in the index pregnancy 
and the treated pregnancy stratified for the presence or absence of known thrombophilic conditions, 
respectively. Severe APO recurred in 4% of treated pregnancies in both groups. The overall 
recurrence rate was identical (26%) in the thrombophilic group and non-thrombophilic group. 
Significant better outcome were observed for feto-maternal complications both for thrombophilic 
and non-thrombophilic patients in the pregnancy treated by LMWH. This different outcome was not 
observed for patients with only maternal complications. 
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DISCUSSION 
In this prospective study we enrolled Caucasian pregnant women with previous severe abnormal 
pregnancy outcome (APO) without any previous uneventful pregnancy or pregnancies treated by 
LMWH. For the purposes of this study early pregnancy loss was not considered an abnormal 
pregnancy outcome. Enrollment was based on natural referral and as a consequence prophylactic 
LMWH was started in the vast majority of cases in the second trimester. 
In this cohort, in which the index pregnancy was classified based on letter of hospital discharge, we 
flagged severe APO whenever any abnormal pregnancy outcome led to iatrogenic delivery ≤32 
weeks of gestation. This severe complication was reported in 53% of feto-maternal APO and in 
18% of maternal only APO. In these patients, treated in the present pregnancy with prophylactic 
doses of LMWH, the overall recurrence of severe outcome with iatrogenic deliveries ≤ 32 weeks of 
gestation decreased from 45% was 4%, the R.R. was 0.3 (CI 95% 0.2-0.8). 
In 100 pregnant women fetal growth restriction was observed in the index pregnancy either as a 
marker of feto-placental disease associated with gestational hypertension, preeclampsia, HELLP, 
and abruption (37 cases), or as fetal condition caused by ―ischemic placental disease‖ [18] without 
maternal clinical signs (63 cases). The severity of these latter cases referred to our Centre was 
underlined by the fact that more than fifty per cent of cases of growth restricted fetuses had ended in 
an intrauterine fetal death in the index pregnancy, and 53% were delivered before 32 weeks of 
gestation. In these treated pregnancies recruited for feto-maternal complications in the index 
pregnancy the recurrence of severe APO was 4%  (R.R. = 0.3; CI .95% 0.1 – 0.8).  
The initiation of LMWH before 24 weeks appeared to be more effective, but this study was not 
designed and powered enough to sort out this difference. 
The 28 pregnancies with maternal APO only in the index pregnancy probably belong to a different 
pathological condition than those with feto-maternal APO. In fact, these latter patients were 
delivered significantly later in gestation, and with significantly better newborn weight than the 
group of patients with associated feto-maternal complications (p<0001). This occurred even though 
their final diagnosis had similar definitions under the present questionable codification of obstetrical 
disease. A non-significant lower recurrence rate was observed for severe APO in these treated 
pregnancies recruited for abnormal maternal outcome only. 
The recurrence rate observed in 100 pregnancies treated by LMWH, based on severity and on 
composite maternal and fetal disease, and not only on the numbers of diseases as coded by present 
International Classification of Diseases, is very much lower than reported recurrence figures for 
severe APO in the first pregnancy both in small cohorts [19-20] and on large population based 
studies [18-21]. A strikingly reduction was observed in the recurrence of abruption. The possible 
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role of LMWH prophylaxis in reducing this severe APO has already been reported by the NOH-AP 
randomized trial 8 [14] in which treatment of pregnancies with previous abruption was started at the 
time of early pregnancy and resulted in a recurrence rate of 10 out of 80 cases in the LMWH treated 
pregnancies versus 25 out of 80 in non treated cases. 
A limitation in our prospective non-randomized study is the possible additional role of ASA in 
patients with previous PE. In fact, 45 patients in our study had been treated with LMWH and ASA 
because of their history of PE. The appropriateness of this regime had been  recently confirmed by a 
recent meta-analysis of Bujold [22] observed a significant reduction of the relative risk (RR=0,45) 
of recurrence in pregnant women treated by ASA before 16 weeks of gestation. We could only 
speculate that this reduction appears to be lower than the one we observed in our cohort in which 
PE was not the single most frequent disease both in index and in treated pregnancy. Indeed, only a 
prospective randomized trial could solve the relative weight of the two regimens. 
Overall, when this cohort was stratified for the presence or absence of thrombophilia the recurrence 
rate of severe APO was 4% both in thrombophilic and non-thrombophilic pregnant women. This is 
very much in agreement with the figures of the small randomized study on LMWH prophylactic 
treatment reported by Rey [13] on non-thrombophilic pregnant women in whom the recurrence rate 
of severe APO in the treated arm was 5.5%. To make a complex problem simple we could say that 
this is in agreement with the statements of Rodger et al [7] that congenital thrombophilia per se has 
not been proven as a cause of placenta mediated pregnancy complications and LMWH might be 
beneficial in preventing placental damage based on its potential immune-modulation besides its 
known antithrombotic rule 30 [23].  
This could be active not only in early gestation by promoting trophoblastic invasion [24] but all 
along placental development and ongoing function. 
When both severe and all APO were considered altogether in the composite recurrence outcome 
analysis, we observed an overall recurrence rate of 25% and 29% for patients with feto-maternal 
and maternal complications in the index pregnancy,  respectively. These findings lay well within the 
huge range reported in literature for observational studies. Even though our small cohort does not fit 
the criteria for a proper epidemiological comparison, when we consider our slightly lower 
percentage of recurrence versus comparable data reported by Likke 5 [21] (37.8% composite 
recurrence rate for preeclampsia occurring between 20 and 36 weeks) we should take into account 
the otherwise much higher recurrence expected in our cohort given the high prevalence of 
intrauterine fetal death [25] and for HELLP 7 [26], which altogether in the group of 100 
pregnancies with feto-maternal complications summed up to 50 cases in the index pregnancy and 
was down to two cases only in the LMWH treated pregnancy. 
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A major growing body of evidence is suggesting that under the names of preeclampsia and 
gestational hypertension there are at least two diseases with different maternal vascular 
abnormalities 13 [27-28-29-30] and quite different placental pathology and fetal growth [31]. 
Recurrence rate in these two subsets should be investigated by different criteria rather than the 
present definition of these syndromes as per the CDI 9. 
Gestational age at diagnosis had been frequently adopted to separate these different diseases, and 
the name early onset and late onset preeclampsia is now used in clinical settings. However, it is 
very likely that this time based criteria are not enough to separate these entities. Placental 
pathology, fetal growth and uterine Doppler waveform, or at least the two latter, should be included 
into this classification. To assess a proper figure of recurrence, Likke [21], Sibai [26-32] and Van 
Rijn [33] corrected the recurrence rate of pregnancies with  ―placental ischemic diseases‖ according 
to gestational age at diagnosis. 
Another confounding factor in assessing the real recurrence of a condition, such as preeclampsia, 
IUGR or abruptio placentae, is that in the subsequent pregnancies these abnormal outcomes are 
interrelated. Ananth [18], on a large series of 154,810 patients, confirmed a crossover of 
preeclampsia, small for gestational age newborns and abruption from one pregnancy to the 
subsequent one. This composite outcome is mandatory to assess the true recurrence rate as 
confirmed by his larger series of 536,419. Both populations studies by Ananth [18], and Lykke [21] 
would have underestimated the recurrence rate of APO from 27.1% to 16.5%, if only preeclampsia 
were tracked in the subsequent pregnancy. 
The finding that in our present cohort pregnancies recruited for previous maternal APO only, 
without clinical evidence of fetal growth restriction, did not show any significant difference 
between index and present pregnancy treated by LMWH in terms of gestational age and weight at 
birth, is in agreement with this criteria to separate early and late onset preeclampsia. 
Beyond speculations, these findings suggest that women with 1 late onset gestational hypertension 
and preeclampsia at their first pregnancy should not be included in randomized studies on LMWH 
role for this could represent a useless recruitment of patients who are not likely to have any benefit 
by LMWH.  
The strength of our findings is based on the strict criteria of recruitment, including homogenous 
ethnicity. Obviously strict monitoring and possibly better treatment regimen in our referral center 
and the strict collaboration between feto-maternal medicine specialists and immune-hematologists 
could have contributed to present results, yet given the state of clinical skills in the geographical 
area of recruitment where the index pregnancies were monitored and treated, we believe that the 
major difference was in fact determined by the usage of LMWH. 
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Major limitations are the non-randomized design of this pilot study and the gestational age at 
recruitment and initiation of therapy, based on the timing of referral. Early placentation was already 
been completed in most of the cases. However, this limitation together with the striking reduction of 
severe APO in recurrence should strongly induce to consider the possible role of LMWH during 
second wave of trophoblastic invasion and all along placental function, and not only from the very 
early stages of placental developmenT [14-34]. 
In conclusion, in this prospective study, prophylactic doses of LMWH after the first trimester 
reduced the recurrence rate of severe composite APO to 4%. These findings confirm that recurrence 
rate of APO in thses studies should consider the overall prevalence as well as severity of recurrence 
and the crossover of different APOs caused by placental ischemic disease. This recurrence rate 
observed in treated pregnancies was in close agreement with the small but significant randomized 
trials [18-19] so far published on LMWH prophylaxis forprevention of APO, and is independent 
from inherited thrombophilic conditions. 
The less significant role of LMWH in reducing the severity and overall recurrence of APOs 
occurring late in pregnancy or without fetal growth restriction addresses the need of overcoming the 
bias induced into any clinical study by present definition of these syndromes as per the CDI 9 which 
groups under the same heading really different diseases. 
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Figure 1 
Flow chart of pregnancy outcome of index pregnancies and subsequent pregnancies treated by 
prophylactic doses of LMWH 
Thin boxes: Index pregnancies. Gestational age and newborn weight (median and i.q.) were 
significantly worse in the feto-maternal than in the maternal APO group (p<0001). The prevalence 
of severe APO was significantly higher in the feto-maternal APO group (p<0.001) 
Thick boxes: treated pregnancies. Feto-maternal APO: gestational age at delivery and newborn 
weight (median and i.q.) in the treated pregnancy were highly significantly better than in the index 
pregnancy (Mann-Whitney test p<0.001). Maternal APO: gestational age at delivery and newborn 
weight in the treated pregnancy were not significantly better than in the index pregnancy (Mann-
Whitney test p<n.s.). The severe and the overall recurrence rate of APO were not significantly 
different in the two groups (p=n.s.). 
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Figure 1 
 
 
  
abnormal maternal outcome 
severe history: 5 (18%) 
abnormal feto-maternal outcome 
severe history : 53 (53%) 
abnormal maternal outcome 
28 patients 
newborn weight 2995g (2245-412) 
week of gestation 37 (34-40) 
 
abnormal feto-maternal outcome 
100 patients 
newborn weight 1430g (850-2200) 
week of gestation 32 (28-37) 
 
abnormal pregnancy outcome 
severe recurrence: 1(4%) 
abnormal pregnancy outcome 
severe recurrence : 4(4%) 
 
 
128 Index Pregnancies with history of APO 
abnormal pregnancy outcome 
overall recurrence: 25 (25%) 
newborn weight 2760g (2407–3085) 
Weeks  38 (36-38) 
abnormal pregnancy outcome 
overall recurrence: 8 (29%) 
newborn weight 2975g  (2450– 3320) 
Weeks  38 (36-38) 
 
128 Treated  Pregnancies by LMWH: 33 (28%)  recurrences of APO 
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Tables 
Table Ia. Analytical description of feto-maternal complications in the index pregnancy and  in the 
treated pregnancy.  Pregnancies delivered ≤32 weeks of gestation were flagged as severe abnormal 
pregnancy outcome (APO).  
index 
pregnancy 
All APO 
Severe 
APO 
treated pregnancy 
 
All APO 
Severe 
APO 
FETO-MATERNAL 
COMPLICATIONS 
100 53 
FETO-MATERNAL 
COMPLICATIONS 
15 1 
GH – PE -  IUGR 17 5 GH – PE -  IUGR 1  
GH – PE -  IUGR -IUFD 6 5  -  
ABRUPTIO  IUGR 6 5  -  
HELLP IUGR 6 3 HELLP IUGR 1  
HELLP IUGR IUFD 2 2  -  
IUGR 27 * 3 IUGR 13 1 
SGA -IUFD 36 30  -  
   
MATERNAL 
COMPLICATIONS 
10 3 
   GH 3  
   PE 2  
   HELLP 1  
   ABRUPTIO 4 3 
TOTAL (%) 100 53 (53%)  25 (25%) 4(4%) 
 
*the median weight of these cases was 1754,4 +/- 991 g and the median gestational age at delivery 
was 34 (r.i. 36-38.5)  
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Table Ib. Analytical description of  maternal  complications in the index pregnancy and  
complications in the treated pregnancy. Pregnancies delivered ≤32 weeks of gestation were flagged 
as severe abnormal pregnancy outcome (APO).  
index 
pregnancy 
 
All APO 
Severe 
APO 
treated pregnancy 
 
All APO 
Severe 
APO 
MATERNAL 
COMPLICATIONS 
28 5 
MATERNAL 
COMPLICATIONS 
2 0 
GH 5      
PREECLAMPSIA 9  2  PREECLAMPSIA 1  
HELLP 5  1     
ABRUPTIO 9 2  ABRUPTIO 1  
   
FETO-MATERNAL 
COMPLICATIONS 
6 1 
   IUGR 6  1 
TOTAL (%) 28  5 (18%)  8 (28%) 1 (4%) 
 
Legend a) and b) panels. 
APO= abnormal pregnancy outcome, excluded first trimester complications; Severe APO = 
abnormal pregnancy outcome which led to iatrogenic delivery before 32 completed weeks of 
gestation; GH = gestational hypertension; PE= preeclampsia; IUGR= intrauterine growth 
restriction; IUFD= intrauterine fetal death; ABRUPTIO= abruption placenta; HELLP = help 
syndrome; SGA= small for gestational age.  
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Table IIA. Fifty inherited thrombophilic patients: Analytical description of  rate and severity of 
recurrence of APO (*).  Pregnancies delivered ≤32 weeks of gestation were flagged as severe 
abnormal pregnancy outcome (APO).  (median and interquartile range in brackets) 
Index pregnancy All APO 
Severe 
APO 
treated pregnancy All APO 
Severe 
APO 
P < 
FETO-
MATERNAL 
COMPLICATION
S  
41  16  
FETO- 
MATERNAL 
COMPLICATIONS  
8  1   
Weeks at delivery 
35  
(30-38) 
 Weeks at delivery 
38  
(36,7-38,25) 
 0,04 
Weight (g.) 
1600 g 
(958-2300) 
 Weight (g.) 
2100 g   
(1990-2395) 
 0,08 
MATERNAL 
COMPLICATION
S  
9 0  
MATERNAL 
COMPLICATIONS  
5 1  
Weeks at delivery 
38 
(36-40) 
 Weeks at delivery 
37 
(35-38) 
 0,41 
Weight (g.) 
3000 g 
(2440-3200) 
 Weight (g.) 
2870 g 
(2290-3180) 
 0,56 
Total 50(100%) 16(32%)   13 (26%) 2 (4%)  
 
(*) 19 women (15,6%) were eterozigotic for V Leiden mutation, 19 women (15,6%) were 
eterozigotic for G20210A prothrombin mutation, 13 (10,1%) were homozigotic for MTHFR 
mutation, two with hyperhomicisteinemia, and 11(8,6%) patients  had more than one mutation. Not 
a single case of S and C deficiency was recorded in this cohort. 
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Table IIB. Non thrombophilic patients: analytical description of  rate and severity of recurrence in . 
Pregnancies delivered ≤32 weeks of gestation were flagged as severe abnormal pregnancy outcome 
(APO).   (median and interquartile range in brackets) 
index pregnancy 
 
All APO 
Severe 
APO 
treated pregnancy 
 
All APO 
Severe 
APO 
P < 
FETO-MATERNAL 
COMPLICATIONS  
59  36  
FETO-MATERNAL 
COMPLICATIONS  
13  1   
Weeks at delivery  
31  
(28-36) 
 Weeks at delivery  
36  
(35-37) 
 0,03 
Weight (g.)  
1295 g  
 (798-2015) 
 Weight (g.)  
2180 g  
 (1890-
2450) 
 0,001 
MATERNAL 
COMPLICATIONS  
19  5  
MATERNAL 
COMPLICATIONS  
7 2   
Weeks at delivery  
36  
(33-39) 
 Weeks at delivery  
37  
(33,5-38) 
 0,97 
Weight (g.)  
2990 g  
 (1945-3415) 
 Weight (g.)  
2650 g  
 (2060-
3085) 
 0,72 
total 78(100%) 41(53%)  20 (26%) 3 (4%)  
 
Legend a) and b) panels. 
APO= abnormal pregnancy outcome, excluded first trimester complications; Severe APO = 
abnormal pregnancy outcome which led to iatrogenic delivery before 32 completed weeks of 
gestation; 
 
 
